Literature DB >> 35121930

KRAS inhibitors, approved.

Rafael Rosell1,2,3, Andrés Aguilar4, Carlos Pedraz5, Imane Chaib5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 35121930     DOI： 10.1038/s43018-021-00289-3

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


× No keyword cloud information.
  3 in total

1.  Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides.

Authors:  Dali Wang; Qiwei Wang; Yuyan Wang; Peiru Chen; Xueguang Lu; Fei Jia; Yehui Sun; Tingyu Sun; Lei Zhang; Fangyuan Che; Jialu He; Liming Lian; Gemma Morano; Michael Shen; Mengqi Ren; Sijia S Dong; Jean J Zhao; Ke Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-14       Impact factor: 12.779

2.  Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?

Authors:  Cristina Andreani; Caterina Bartolacci; Pier Paolo Scaglioni
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

3.  Ablating lung cancer, knowing the tumor better.

Authors:  Rafael Rosell; María González-Cao
Journal:  Lancet Reg Health Eur       Date:  2022-08-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.